Neurona Therapeutics key facts
as of Oct 2026- Developer of regenerative cell therapies designed for the treatment of chronic neurological disorders.
- Neurona Therapeutics is valued at approximately $1.1B as of Oct 2026, per PrivateMarketView’s mark.
- It has raised $347.6M across 6 recorded rounds; the latest was Later Stage VC (Series F) ($101.7M) in Mar 2025.
- Notable investors include Fidelity Management & Research Company, Viking Global Investors, National Institutes of Health, University of California, Alexandria Venture Investments — 30 tracked in total.
- 2 institutional filers report fund marks on Neurona Therapeutics across 35 filings.
- Neurona Therapeutics has filed 8 Form Ds with the SEC since 2014, most recently Apr 2025 ($101.7M sold to 46 investors).
- Status: Privately Held (backing).
Fund marks imply 1/98 of the round — treated as a units change, held — shown at a merger or acquisition, Apr 2026 ($1.1B post-money).
- ·The complete investor list: 30 names
- ·Watch Neurona Therapeutics: the Monday email on marks, rounds and moves
Institutional fund marks on Neurona Therapeutics
2 filers · latest Jul 20262 SEC-registered funds reported 35 fair-value marks on Neurona Therapeutics between Apr 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
Neurona Therapeutics funding rounds
6 roundsWho backs Neurona Therapeutics
30+Membership and data by Private Market View
Neurona Therapeutics valuation
Neurona Therapeutics is valued at approximately $1.1 billion as of Oct 2026. The figure is set by institutional fund marks. The reference point is a merger or acquisition in Apr 2026, at a $1.1 billion post-money valuation.
Recent activity
In the last 90 days, Neurona Therapeutics's record added 15 institutional fund marks (latest period Jul 2026).
How much has Neurona Therapeutics raised?
Neurona Therapeutics has raised $348 million across 6 recorded rounds since 2014. The largest was a $72 million later-stage round in Mar 2021; the most recent was a $102 million Series F in Mar 2025.
Neurona Therapeutics has filed 8 Form Ds with the SEC since 2014, most recently in Apr 2025 ($102 million sold to 46 investors).
Institutional holders and vehicles
2 SEC-registered funds reported 35 fair-value marks on Neurona Therapeutics between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Neurona Therapeutics investors
30 investors are on record for Neurona Therapeutics, including Fidelity Management & Research Company, Viking Global Investors, National Institutes of Health and University of California. The Series F in Mar 2025 drew 15 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Areteia Therapeutics ($1.3 billion), Parabilis Medicines ($920 million) and Bluejay Therapeutics ($820 million).
About Neurona Therapeutics
Developer of regenerative cell therapies designed for the treatment of chronic neurological disorders. The company provides allogeneic, off-the-shelf neural cell therapies that integrate into neural circuits, replace affected cells, and rebalance electrical activity, enabling medical practitioners to offer patients with chronic neurological conditions long-lasting disease amelioration from a single, one-time dose.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2008
- Employees
- 105
- Website
- neuronatherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.